A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

To characterize the pharmacokinetics (PK) properties of LY4170156: Minimum Plasma Concentration (Cmin)

PK: Cmin of LY4170156

Time frame: First 4 Cycles (84 days)

To characterize the PK properties of LY4170156: Cmin with bevacizumab or carboplatin

PK: Cmin of LY4170156

Time frame: First 4 Cycles (Approximately 84 days)

To characterize the PK properties of LY4170156: Cmin with pembrolizumab

PK: Cmin of LY4170156

Time frame: First 4 Cycles (84 days)

To characterize the PK properties of LY4170156: Area under the concentration versus time curve (AUC)

PK: AUC of LY4170156

Time frame: First 4 Cycles (84 days)

To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR)

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR)

DOR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab

DOR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR)

TTR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab

TTR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS)

PFS per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab

PFS per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years]

To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR)

DCR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years

To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab

DCR per investigator assessed RECIST 1.1

Time frame: Up to Approximately 48 Months or 4 Years